OM
PRVB

Opaleye Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Opaleye Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-166,000
Closed -$1.53M – 55
2020
Q1 		$1.53M Buy
+166,000
New +$2.14M 0.4% 39

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's PRVB Position: Q2 2020 in Review

Opaleye Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2020, closing a stake of 166,000 shares — an estimated $1.53M sold.

Opaleye Management first reported a position in PRVB in Q1 2020 and held it in 1 quarter. The position peaked at $1.53M in Q1 2020. 106 funds tracked by Wall St. Rank hold PRVB as of Q2 2020.

  • Opaleye Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Opaleye Management sold 166,000 Provention Bio, Inc. Common Stock shares in Q2 2020, an estimated $1.53M.
  • Opaleye Management first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Opaleye Management's Provention Bio, Inc. Common Stock position peaked at $1.53M in Q1 2020.
  • 106 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2020.

Based on Opaleye Management's 13F filing for Q2 2020, filed 14 Aug 2020.